Inhibition of the immunoproteasome LMP2 ameliorates ischemia/hypoxia-induced blood-brain barrier injury through the Wnt/β-catenin signalling pathway.

"Declarations Ethics approval and consent to participateAll experiments were approved by the Institutional Animal Ethical Committee of Fujian Medical University (No. FJMUIACUC2020-0059). Consent for publicationAll of the authors agree to the submission and consent for publication this paper. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by National Natural Science Foundation of China (81771250); the Natural Science Foundation of Fujian Province, China (2020J011059, 2020R1011004); the Joint Funds for the Innovation of Science and Technology of Fujian Province, China (2017Y9065); and the High-level hospital foster grants from Fujian Provincial Hospital, Fujian province, China (2020HSJJ07)."